Trials / Completed
CompletedNCT01032486
Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease
An Open-Label, Multi-Center, Single Arm Study to Evaluate the Effects of Azilect® on Sleep Disturbances in Parkinson's Disease Subjects
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the effect of Azilect® on sleep disturbances in Parkinson's Disease patients, after 2 months of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rasagiline mesylate | Azilect® tablets (0.5mg or 1.0 mg) administered orally once daily |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2011-06-01
- Completion
- 2011-07-01
- First posted
- 2009-12-15
- Last updated
- 2013-08-28
Source: ClinicalTrials.gov record NCT01032486. Inclusion in this directory is not an endorsement.